You are now leaving GSK’s website

You are now leaving a GSK Website. By clicking this link, you will be taken to a website that is not owned or controlled by GSK, and GSK is not responsible for the content provided on that site.


Go back

Coming soon

Sorry, we are still working on this page.
Be the first to find out about our new Zejula (niraparib) portal page by signing up with GSKPro.

Patient Resources

Order or Download our Zejula patient information booklet below.

Adverse events should be reported directly to the Health Products Regulatory Authority (HPRA) on their website: . Adverse events should also be reported to GlaxoSmithKline on 1800 244 255.

This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.

November 2021 | PM-IE-NRP-WCNT-210008